4
Changes in Ownership
Pacira BioSciences, Inc. Filed Acc 0001628280-25-056645
Chief Financial Officer sold 25,000 shares at an average $25.07 ($626,751)
- Chief Financial Officer acquired 25,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Cross Shawn Chief Financial Officer | 2025-12-09 | Option exercise 10b5-1 | +15,896 | $16.45 | $261,489 | 72,146 | D |
| Cross Shawn Chief Financial Officer | 2025-12-09 | Sale 10b5-1 | −15,896 | $25.03 | $397,877 | 56,250 | D |
| Cross Shawn Chief Financial Officer | 2025-12-10 | Option exercise 10b5-1 | +9,104 | $16.45 | $149,761 | 65,354 | D |
| Cross Shawn Chief Financial Officer | 2025-12-10 | Sale 10b5-1 | −9,104 | $25.14 | $228,875 | 56,250 | D |
| Derivatives | |||||||
| Cross Shawn Chief Financial Officer | 2025-12-09 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,896 | 184,104 | D | ||
| Cross Shawn Chief Financial Officer | 2025-12-10 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,104 | 175,000 | D | ||
| Open-market sales · 25,000 sh · avg $25.07 · $626,751 | |||||||
Loading xslF345X05/wk-form4_1765507617.xml…